Literature DB >> 18568538

Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization.

B Wang1, H Xu, Z Q Gao, H F Ning, Y Q Sun, G W Cao.   

Abstract

BACKGROUND: Changes in the biological behavior of residual viable hepatocellular carcinoma (HCC) tissue after transcatheter arterial chemoembolization (TACE) remain unclear. Several studies have reported that TACE inhibits tumor angiogenesis and induces tumor cell apoptosis, while other studies have found that TACE stimulates tumor angiogenesis and thus increases the proliferative activity of the tumor cells to some degree.
PURPOSE: To investigate the intratumoral microvessel density (MVD) and vascular endothelial growth factor (VEGF) expression in residual surviving cancerous tissue after TACE in HCC.
MATERIAL AND METHODS: Tumor specimens from 63 histopathologically diagnosed patients were studied: 42 comprising the control group (treated by surgery alone) and 21 comprising the TACE group (those treated by TACE 1-2 times prior to surgical resection). The number of VEGF-positive cells, MVD, and microvessel diameter were measured.
RESULTS: The MVD was 51.69+/-18.17 and 58.57+/-15.75 in the control and TACE groups, respectively. There was no significant difference between the two groups (t=1.48, P>0.05). The microvessel diameter was 17.62+/-10.54 microm and 15.79+/-7.65 microm in the control and TACE groups, respectively, indicating no significant difference between the two groups (t=0.71, P>0.05). The number of VEGF-positive cells in the TACE group, i.e., 243.66+/-88.88, was higher than that in the control group, i.e., 138.26+/-65.24 (t=5.34, P<0.01). TACE increased VEGF expression in the residual surviving HCC tissues, and there was a positive correlation between VEGF expression and MVD (r=0.4936, t=4.4329, P<0.05) in the HCC tissue.
CONCLUSION: The study indicates that the residual surviving cancerous tissue in HCC after TACE has a rich vascularity. TACE increases VEGF expression in the residual surviving cancerous tissue.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18568538     DOI: 10.1080/02841850801958890

Source DB:  PubMed          Journal:  Acta Radiol        ISSN: 0284-1851            Impact factor:   1.990


  118 in total

1.  Electroporation-mediated transcatheter arterial chemoembolization in the rabbit VX2 liver tumor model.

Authors:  Yang Guo; Yue Zhang; Ning Jin; Rachel Klein; Jodi Nicolai; Robert J Lewandowski; Robert K Ryu; Reed A Omary; Andrew C Larson
Journal:  Invest Radiol       Date:  2012-02       Impact factor: 6.016

Review 2.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

3.  A preclinical study on the combination therapy of everolimus and transarterial chemoembolization in hepatocellular carcinoma.

Authors:  Ariel Km Chow; Thomas Cc Yau; Lui Ng; Andrew Cy Chu; Wai-Lun Law; Ronnie Tp Poon; Roberta Wc Pang
Journal:  Am J Cancer Res       Date:  2015-07-15       Impact factor: 6.166

4.  Influence of preoperative transcatheter arterial chemoembolization on gene expression in the HIF-1α pathway in patients with hepatocellular carcinoma.

Authors:  Weiguang Xu; Jung-Hee Kwon; Young Ho Moon; Young Bae Kim; Yun Suk Yu; Namgyu Lee; Kwan Yong Choi; Yun Soo Kim; Yong Keun Park; Bong Wan Kim; Hee Jung Wang
Journal:  J Cancer Res Clin Oncol       Date:  2014-05-23       Impact factor: 4.553

5.  Comprehensive treatments for hepatocellular carcinoma with tumor thrombus in major portal vein.

Authors:  Hai-Hong Ye; Jia-Zhou Ye; Zhi-Bo Xie; Yu-Chong Peng; Jie Chen; Liang Ma; Tao Bai; Jun-Ze Chen; Zhan Lu; Hong-Gui Qin; Bang-De Xiang; Le-Qun Li
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

Review 6.  Role of the tissue microenvironment as a therapeutic target in hepatocellular carcinoma.

Authors:  Bhavna Rani; Yuan Cao; Andrea Malfettone; Ciprian Tomuleasa; Isabel Fabregat; Gianluigi Giannelli
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Arsenic trioxide: marked suppression of tumor metastasis potential by inhibiting the transcription factor Twist in vivo and in vitro.

Authors:  Guang-Zhi Wang; Wei Zhang; Zhu-Ting Fang; Wen Zhang; Min-Jie Yang; Guo-Wei Yang; Shuo Li; Lian Zhu; Li-Li Wang; Wei-Sheng Zhang; Rong Liu; Sheng Qian; Jian-Hua Wang; Xu-Dong Qu
Journal:  J Cancer Res Clin Oncol       Date:  2014-04-23       Impact factor: 4.553

8.  Proposal of Primary Endpoints for TACE Combination Trials with Systemic Therapy: Lessons Learned from 5 Negative Trials and the Positive TACTICS Trial.

Authors:  Masatoshi Kudo
Journal:  Liver Cancer       Date:  2018-08-23       Impact factor: 11.740

Review 9.  Chemoembolization of hepatocellular carcinoma.

Authors:  Riccardo Lencioni; Pasquale Petruzzi; Laura Crocetti
Journal:  Semin Intervent Radiol       Date:  2013-03       Impact factor: 1.513

10.  Sorafenib in combination with transarterial chemoembolization and radiofrequency ablation in the treatment for unresectable hepatocellular carcinoma.

Authors:  Yong Li; You-Bing Zheng; Wei Zhao; Bing Liu; Bao-Shan Hu; Xu He; Jian-Wen Huang; Li-Gong Lu
Journal:  Med Oncol       Date:  2013-09-19       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.